X0306 4 2021-02-24 0 0001549595 Nurix Therapeutics, Inc. NRIX 0001817217 van Houte Hans C/O NURIX THERAPEUTICS, INC. 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 0 1 0 0 Chief Financial Officer Common Stock 2021-02-24 4 M 0 20393 1.20 A 20393 D Common Stock 2021-02-24 4 M 0 13197 1.86 A 33590 D Common Stock 2021-02-24 4 M 0 1829 7.26 A 35419 D Common Stock 2021-02-24 4 S 0 35419 39.90 D 0 D Employee Stock Option (right to buy) 1.20 2021-02-24 4 M 0 20393 0.00 D 2028-03-01 Common Stock 20393 9027 D Employee Stock Option (right to buy) 1.86 2021-02-24 4 M 0 13197 0.00 D 2029-08-28 Common Stock 13197 20136 D Employee Stock Option (right to buy) 7.26 2021-02-24 4 M 0 1829 0.00 D 2030-02-26 Common Stock 1829 36504 D This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. The stock option vests as to 1/48 of the total shares monthly beginning February 2, 2018 until the option is fully vested on January 2, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. The stock option vests as to 1/48 of the total shares monthly beginning June 10, 2019 until the option is fully vested on May 10, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. The stock option vests as to 1/48 of the total shares monthly beginning February 18, 2020 until the option is fully vested on January 18, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The option contains an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase. /s/ Christine Ring, as Attorney-in-Fact for Hans van Houte 2021-02-25